The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: A mechanism of action study

Retrovirology

Volumn 6, Issue , 2009, Pages

  Feng, Joy Y ^a   Ly, John K ^a   Myrick, Florence ^a   Goodman, Derrick ^a   White, Kirsten L ^a   Svarovskaia, Evguenia S ^a   Borroto Esoda, Katyna ^a   Miller, Michael D ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; RNA DIRECTED DNA POLYMERASE; TENOFOVIR; VIRUS DNA; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; DEOXYCYTIDINE; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE; REVERSE TRANSCRIPTASE, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG STABILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; MOLECULAR DYNAMICS; PHOSPHORYLATION; VIRUS REPLICATION; BIOSYNTHESIS; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENINE; ANTI-HIV AGENTS; BENZOXAZINES; CELL LINE; DEOXYCYTIDINE; DNA, VIRAL; DRUG SYNERGISM; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; PHOSPHONIC ACIDS; VIRUS REPLICATION;

EID: 67649553022     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-44     Document Type: Article

References (69)

1. Sharma PL Nurpeisov V Hernandez-Santiago B Beltran T Schinazi RF Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase Curr Top Med Chem 2004, 4:895-919 10.2174/1568026043388484 15134548
2. Deval J Courcambeck J Selmi B Boretto J Canard B Structural determinants and molecular mechanisms for the resistance of HIV-1 RT to nucleoside analogues Curr Drug Metab 2004, 5:305-316 10.2174/1389200043335478 15320702
3. White KL Margot NA Ly JK Chen JM Ray AS Pavelko M Wang R McDermott M Swaminathan S Miller MD A combination of decreased NRTI incorporation and decreased excision determines the resistance profile of HIV-1 K65R RT Aids 2005, 19:1751-1760 10.1097/01.aids.0000189851.21441.f1 16227782
4. Menendez-Arias L Mechanisms of resistance to nucleoside analogue inhibitors of HIV-1 reverse transcriptase Virus Res 2008, 134:124-146 10.1016/j.virusres.2007.12.015 18272247
5. Sluis-Cremer N Tachedjian G Mechanisms of inhibition of HIV replication by non-nucleoside reverse transcriptase inhibitors Virus Res 2008, 134:147-156 10.1016/j.virusres.2008.01.002 18372072
6. Balzarini J Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 Curr Top Med Chem 2004, 4:921-944 10.2174/1568026043388420 15134549
7. Richman D Rosenthal AS Skoog M Eckner RJ Chou TC Sabo JP Merluzzi VJ BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine Antimicrob Agents Chemother 1991, 35:305-308 244996 1708976
8. Pauwels R Andries K Debyser Z Kukla MJ Schols D Breslin HJ Woestenborghs R Desmyter J Janssen MA De Clercq E et al New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2′,3′-dideoxynucleoside analogs Antimicrob Agents Chemother 1994, 38:2863-2870 188298 7535037
9. Brennan TM Taylor DL Bridges CG Leyda JP Tyms AS The inhibition of human immunodeficiency virus type 1 in vitro by a non-nucleoside reverse transcriptase inhibitor MKC-442, alone and in combination with other anti-HIV compounds Antiviral Res 1995, 26:173-187 10.1016/ 0166-3542(94)00074-I 7541619
10. Chong KT Pagano PJ Inhibition of human immunodeficiency virus type 1 infection in vitro by combination of delavirdine, zidovudine and didanosine Antiviral Res 1997, 34:51-63 10.1016/S0166-3542(96)01021-2 9107385
11. Buckheit RW Jr Watson K Fliakas-Boltz V Russell J Loftus TL Osterling MC Turpin JA Pallansch LA White EL Lee JW et al SJ- a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2 Antimicrob Agents Chemother 3366, 45:393-400 10.1128/ AAC.45.2.393-400.2001
12. King RW Klabe RM Reid CD Erickson-Viitanen SK Potency of nonnucleoside reverse transcriptase inhibitors (NNRTIs) used in combination with other human immunodeficiency virus NNRTIs, NRTIs, or protease inhibitors Antimicrob Agents Chemother 2002, 46:1640-1646 127223 12019069 10.1128/ AAC.46.6.1640-1646.2002
13. Carroll SS Stahlhut M Geib J Olsen DB Inhibition of HIV-1 reverse transcriptase by a quinazolinone and comparison with inhibition by pyridinones. Differences in the rates of inhibitor binding and in synergistic inhibition with nucleoside analogs J Biol Chem 1994, 269:32351-32357 7528214
14. Zhang H Vrang L Rydergard C Ahgren C Oberg B Synergistic inhibition of HIV-1 reverse transcriptase and HIV-1 replication by combining trovirdine with AZT, ddI and dC in vitro Antivir Chem Chemother 1996, 7:221-229
15. Maga G Hubscher U Pregnolato M Ubiali D Gosselin G Spadari S Potentiation of inhibition of wild-type and mutant human immunodeficiency virus type 1 reverse transcriptases by combinations of nonnucleoside inhibitors and d- and L-(beta)-dideoxynucleoside triphosphate analogs Antimicrob Agents Chemother 2001, 45:1192-1200 90443 11257034 10.1128/AAC.45.4.1192-1200.2001
16. Carr A Vella S de Jong MD Sorice F Imrie A Boucher CA Cooper DA A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group Aids 1996, 10:635-641 8780818
17. Borkow G Arion D Wainberg MA Parniak MA The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1 Antimicrob Agents Chemother 1999, 43:259-263 89060 9925515
18. Odriozola L Cruchaga C Andreola M Dolle V Nguyen CH Tarrago-Litvak L Perez-Mediavilla A Martinez-Irujo JJ Non-nucleoside inhibitors of HIV-1 reverse transcriptase inhibit phosphorolysis and resensitize the 3′-azido-3′-deoxythymidine (AZT)-resistant polymerase to AZT-5′-triphosphate J Biol Chem 2003, 278:42710-42716 10.1074/ jbc.M212673200 12917424
19. Cruchaga C Odriozola L Andreola M Tarrago-Litvak L Martinez-Irujo JJ Inhibition of phosphorolysis catalyzed by HIV-1 reverse transcriptase is responsible for the synergy found in combinations of 3′-azido-3′-deoxythymidine with nonnucleoside inhibitors Biochemistry 2005, 44:3535-3546 10.1021/bi048129z 15736963
20. Basavapathruni A Bailey CM Anderson KS Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs J Biol Chem 2004, 279:6221-6224 10.1074/jbc.C300523200 14722107
21. Radzio J Sluis-Cremer N Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision Mol Pharmacol 2008, 73:601-606 10.1124/mol.107.038596 18024510
22. Dornsife RE St Clair MH Huang AT Panella TJ Koszalka GW Burns CL Averett DR Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells Antimicrob Agents Chemother 1991, 35:322-328 244999 1708977
23. Johnson VA Merrill DP Videler JA Chou TC Byington RE Eron JJ D'Aquila RT Hirsch MS Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro J Infect Dis 1991, 164:646-655 1716649
24. Yarchoan R Lietzau JA Nguyen BY Brawley OW Pluda JM Saville MW Wyvill KM Steinberg SM Agbaria R Mitsuya H et al A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection J Infect Dis 1994, 169:9-17 7903976
25. Periclou AP Nandy P Avramis VI Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT) In Vivo 2000, 14:377-388 10904870
26. Parker WB Shaddix SC Bowdon BJ Rose LM Vince R Shannon WM Lee Bennett LJ Metabolism of carbovir, a potent inhibitor of human immunodeficiency virus type 1, and its effects on cellular metabolism Antimicrob Agents Chemother 1993, 37:1004-1009 187879 7685993
27. Eron JJ Jr Johnson VA Merrill DP Chou TC Hirsch MS Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2′,3′-dideoxycytidine in vitro Antimicrob Agents Chemother 1992, 36:1559-1562 191620 1324648
28. Bridges EG Dutschman GE Gullen EA Cheng YC Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus Biochem Pharmacol 1996, 51:731-736 10.1016/0006-2952(96)00056-1 8602867
29. Mulato AS Cherrington JM Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: In vitro analyses Antiviral Res 1997, 36:91-97 10.1016/S0166-3542(97)00043-0 9443665
30. Borroto-Esoda K Vela JE Myrick F Ray AS Miller MD In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine Antivir Ther 2006, 11:377-384 16759055
31. Perez-Olmeda M Garcia-Perez J Mateos E Spijkers S Ayerbe MC Carcas A Alcami J In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication J Med Virol 2009, 81:211-216 10.1002/jmv.21377 19107982
32. Ray AS Myrick F Vela JE Olson LY Eisenberg EJ Borroto-Esodo K Miller MD Fridland A Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine Antivir Ther 2005, 10:451-457 15918336
33. White EL Parker WB Ross LJ Shannon WM Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5′-triphosphates of various anti-HIV nucleoside analogs Antiviral Res 1993, 22:295-308 10.1016/0166-3542(93)90039-L 7506513
34. Villahermosa ML Martinez-Irujo JJ Cabodevilla F Santiago E Synergistic Inhibition of HIV-1 Reverse Transcriptase by Combinations of Chain-Terminating Nucleotides Biochemistry 1997, 36:13223-13231 10.1021/ bi970852k 9341211
35. Greco WR Bravo G Parsons JC The search for synergy: A critical review from a response surface perspective Pharmacol Rev 1995, 47:331-385 7568331
36. Prichard MN Shipman C Jr Analysis of combinations of antiviral drugs and design of effective multidrug therapies Antivir Ther 1996, 1:9-20 11322261
37. Martinez-Irujo JJ Villahermosa ML Alberdi E Santiago E A checkerboard method to evaluate interactions between drugs Biochem Pharmacol 1996, 51:635-644 10.1016/S0006-2952(95)02230-9 8615900
38. Chou TC Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands J Theor Biol 1976, 59:253-276 10.1016/ 0022-5193(76)90169-7 957690
39. Chou TC Talaly P A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems J Biol Chem 1977, 252:6438-6442 893418
40. Elion GB Singer S Hitchings GH Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites J Biol Chem 1954, 208:477-488 13174557
41. Selleseth DW Talarico CL Miller T Lutz MW Biron KK Harvey RJ Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication Antimicrob Agents Chemother 2003, 47:1468-1471 152503 12654696 10.1128/AAC.47.4.1468-1471.2003
42. Prichard MN Prichard LE Shipman C Jr Strategic design and three-dimensional analysis of antiviral drug combinations Antimicrob Agents Chemother 1993, 37:540-545 187704 8384816
43. Yonetani T Theorell H Studies on Liver Alcohol Hydrogenase Complexes. 3. Multiple Inhibition Kinetics in the Presence of Two Competitive Inhibitors Arch Biochem Biophys 1964, 106:243-251 10.1016/ 0003-9861(64)90184-5 14217165
44. Killingley B Pozniak A The first once-daily single-tablet regimen for the treatment of HIV-infected patients Drugs Today (Barc) 2007, 43:427-442 10.1358/dot.2007.43.7.1086178 17728844
45. Hawkins T Veikley W St Claire RL 3rd Guyer B Clark N Kearney BP Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens J Acquir Immune Defic Syndr 2005, 39:406-411 10.1097/01.qai.0000167155.44980.e8 16010161
46. Wang LH Begley J St Claire RL 3rd Harris J Wakeford C Rousseau FS Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection AIDS Res Hum Retroviruses 2004, 20:1173-1182 10.1089/aid.2004.20.1173 15588339
47. Drusano GL D'Argenio DZ Bilello PA McDowell J Sadler B Bye A Bilello JA Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro Antimicrob Agents Chemother 1998, 42(9):2153-2159 105760 9736527
48. Taylor DL Ahmed PS Tyms AS Wood LJ Kelly LA Chambers P Clarke J Bedard J Bowlin TL Rando RF Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/ -)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC] Antivir Chem Chemother 2000, 11:291-301 10950391
49. Meyer PR Matsuura SE Mian AM So AG Scott WA A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase Mol Cell 1999, 4:35-43 10.1016/ S1097-2765(00)80185-9 10445025
50. Isel C Ehresmann C Walter P Ehresmann B Marquet R The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase J Biol Chem 2001, 276:48725-48732 10.1074/jbc.M108352200 11668180
51. Tong W Lu CD Sharma SK Matsuura S So AG Scott WA Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase Biochemistry 1997, 36:5749-5757 10.1021/bi962410z 9153415
52. Gao H-Q Boyer PL Sarafianos SG Arnold E Hughes SH The role of steric hindrance in 3TC resistance of human immunodeficiency virus type-1 reverse transcriptase J Mol Biol 2000, 300:403-418 10.1006/ jmbi.2000.3823 10873473
53. Gao W-Y Cara A Gallo RC Lori F Low levels of deoxynulceotides in peripheral blood lymphocytes: A strategy to inhibit human immunodeficiency virus type 1 replication Proc Natl Acad Sci USA 1993, 90:8925-8928 47473 7692440 10.1073/pnas.90.19.8925
54. Traut T Physiological concentrations of purines and pyrimidines Mol Cell Biochem 1994, 140:1-22 10.1007/BF00928361 7877593
55. Marchand B White KL Ly JK Margot NA Wang R McDermott M Miller MD Gotte M Effects of the translocation status of human immunodeficiency virus type 1 reverse transcriptase on the efficiency of excision of tenofovir Antimicrob Agents Chemother 2007, 51:2911-2919 1932533 17517852 10.1128/ AAC.00314-07
56. Sustiva (efavirenz) package insert http://packageinserts.bms.com/pi/ pi_sustiva.pdf
57. Abbondanzieri EA Bokinsky G Rausch JW Zhang JX Le Grice SF Zhuang X Dynamic binding orientations direct activity of HIV reverse transcriptase Nature 2008, 453:184-189 2655135 18464735 10.1038/ nature06941
58. Grobler JA Dornadula G Rice MR Simcoe AL Hazuda DJ Miller MD HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro J Biol Chem 2007, 282:8005-8010 10.1074/jbc.M608274200 17172472
59. White KL Chen JM Feng JY Margot NA Ly JK Ray AS Macarthur HL McDermott MJ Swaminathan S Miller MD The K65R reverse transcriptase mutation in HIV-1 reverses the excision phenotype of zidovudine resistance mutations Antivir Ther 2006, 11:155-163 16640096
60. Shi C Mellors JW A recombinant retroviral system for rapid in vivo analysis of human immunodeficiency virus type 1 susceptibility to reverse transcriptase inhibitors Antimicrob Agents Chemother 1997, 41:2781-2785 164210 9420060
61. Weislow OS Kiser R Fine DL Bader J Shoemaker RH Boyd MR New soluble-formazan assay for HIV-1 cytopathic effects: Application to high-flux screening of synthetic and natural products for AIDS-antiviral activity J Natl Cancer Inst 1989, 81:577-586 10.1093/jnci/81.8.577 2495366
62. Chou TC Talalay P Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 1984, 22:27-55 10.1016/0065-2571(84)90007-4 6382953
63. Prichard MN Shipman C Jr A three-dimensional model to analyze drug-drug interactions Antiviral Res 1990, 14 :81-205 10.1016/0166-3542(90)90001-N 2088205
64. Berenbaum MC Synergy, additivism and antagonism in immunosuppression Clin Exp Immunol 1977, 28:1-18 1540873 324671
65. Tramontano E Cheng YC HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative: BI-RG-587 Biochem Pharmacol 1992, 43:1371-1376 10.1016/0006-2952(92)90515-K 1373283
66. Gu Z Quan Y Li Z Arts EJ Wainberg MA Effects of non-nucleoside inhibitors of human immunodeficiency virus type 1 in cell-free recombinant reverse transcriptase assays J Biol Chem 1995, 270:31046-31051 10.1074/jbc.270.19.11238 8537362
67. Balzarini J Perez-Perez MJ San-Felix A Camarasa MJ Bathurst IC Barr PJ De Clercq E Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2′,5′-bis-O-(tert-butyldimethylsilyl)-beta-D -ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″ -oxathiole-2 ″,2 ″-dioxide)thymine (TSAO-T) J Biol Chem 1992, 267:11831-11838 1376314
68. Martinez-Irujo JJ Villahermosa ML Mercapide J Cabodevilla JF Santiago E Analysis of the combined effect of two linear inhibitors on a single enzyme Biochem J 1998, 329(Pt 3):6890-698 1219094 9445400
69. Kati WM Johnson KA Jerva LF Anderson KS Mechanism and fidelity of HIV reverse transcriptase J Biol Chem. 1992, 267(36):25988-25997 1281479